Enhancing vaccine safety capacity globally: A lifecycle perspective

被引:32
作者
Chen, Robert T. [1 ]
Shimabukuro, Tom T. [1 ]
Martin, David B. [2 ]
Zuber, Patrick L. P. [3 ]
Weibel, Daniel M. [4 ]
Sturkenboom, Miriam [4 ]
机构
[1] Ctr Dis Control & Prevent, Off Infect Dis, Atlanta, GA USA
[2] US FDA, Off Biostat & Epidemiol, Ctr Biol Evaluat & Res, Silver Spring, MD USA
[3] WHO, CH-1211 Geneva, Switzerland
[4] Erasmus Univ, Med Ctr, Rotterdam, Netherlands
关键词
Vaccine safety; AEFI; Sustainability; Capacity building; LMICs; GUILLAIN-BARRE-SYNDROME; INACTIVATED POLIOVIRUS VACCINATION; REPORTING SYSTEM VAERS; MUMPS-RUBELLA VACCINE; UNITED-STATES; ADVERSE EVENTS; INFLUENZA VACCINE; CUTTER INCIDENT; IMMUNIZATION PRACTICES; CHILDHOOD VACCINATION;
D O I
10.1016/j.vaccine.2015.06.073
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Major vaccine safety controversies have arisen in several countries beginning in the last decades of 20th century. Such periodic vaccine safety controversies are unlikely to go away in the near future as more national immunization programs mature with near elimination of target vaccine-preventable diseases that result in relative greater prominence of adverse events following immunizations, both true reactions and temporally coincidental events. There are several ways in which vaccine safety capacity can be improved to potentially mitigate the impact of future vaccine safety controversies. This paper aims to take a "lifecycle" approach, examining some potential pre- and post-licensure opportunities to improve vaccine safety, in both developed (specifically U.S. and Europe) and low- and middle-income countries. (C) 2015 by American Journal of Preventive Medicine and Elsevier Ltd. All rights reserved.
引用
收藏
页码:D46 / D54
页数:9
相关论文
共 152 条
[41]  
ECDC, 2012, NARC ASS PAND INFL V
[42]  
Elam-Evans LD, 2014, MMWR-MORBID MORTAL W, V63, P741
[43]   Evaluating the safety of new vaccines: Summary of a workshop [J].
Ellenberg, SS ;
Foulkes, MA ;
Midthun, K ;
Goldenthal, KL .
AMERICAN JOURNAL OF PUBLIC HEALTH, 2005, 95 (05) :800-807
[44]   A global regulatory science agenda for vaccines [J].
Elmgren, Lindsay ;
Li, Xuguang ;
Wilson, Carolyn ;
Ball, Robert ;
Wang, Junzhi ;
Cichutek, Klaus ;
Pfleiderer, Michael ;
Kato, Atsushi ;
Cavaleri, Marco ;
Southern, James ;
Jivapaisarnpong, Teeranart ;
Minor, Philip ;
Griffiths, Elwyn ;
Sohn, Yeowon ;
Wood, David .
VACCINE, 2013, 31 :B163-B175
[45]   ADVERSE-DRUG-REACTION MONITORING [J].
FAICH, GA .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (24) :1589-1592
[46]   A NEW METHOD FOR ACTIVE SURVEILLANCE OF ADVERSE EVENTS FROM DIPHTHERIA-TETANUS-PERTUSSIS AND MEASLES MUMPS RUBELLA VACCINES [J].
FARRINGTON, P ;
PUGH, S ;
COLVILLE, A ;
FLOWER, A ;
NASH, J ;
MORGANCAPNER, P ;
RUSH, M ;
MILLER, E .
LANCET, 1995, 345 (8949) :567-569
[47]   Maternal vaccination: moving the science forward [J].
Faucette, Azure N. ;
Unger, Benjamin L. ;
Gonik, Bernard ;
Chen, Kang .
HUMAN REPRODUCTION UPDATE, 2015, 21 (01) :119-135
[48]   INDIVIDUAL VERSUS PUBLIC PRIORITIES IN THE DETERMINATION OF OPTIMAL VACCINATION POLICIES [J].
FINE, PEM ;
CLARKSON, JA .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1986, 124 (06) :1012-1020
[49]  
Food and Drug Administration, 2020, MEN LAB RUL KEY FACT
[50]   Vaccine safety controversies and the future of vaccination programs [J].
François, G ;
Duclos, P ;
Margolis, H ;
Lavanchi, D ;
Siegrist, CA ;
Meheus, A ;
Lambert, PH ;
Emiroglu, N ;
Badur, S ;
Van Damme, P .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2005, 24 (11) :953-961